中华皮肤科杂志
中華皮膚科雜誌
중화피부과잡지
Chinese Journal of Dermatology
2013年
9期
676-678
,共3页
石丽君%曾抗%李利豪%吴海娟%邹循辉%黄小雄
石麗君%曾抗%李利豪%吳海娟%鄒循輝%黃小雄
석려군%증항%리리호%오해연%추순휘%황소웅
目的 探讨卡介菌多糖核酸(BCG-PSN)联合西替利嗪治疗慢性荨麻疹患者,血浆嗜酸性粒细胞趋化因子(eotaxin)、肿瘤坏死因子(TNF)α和干扰素(IFN)γ水平的检测.方法 用BCG-PSN联合西替利嗪治疗慢性荨麻疹患者,其中联合用药组60例、单独用药组63例,观察两种治疗方案的临床疗效;分别于治疗前、后采集患者和56例健康对照者外周静脉血;ELISA法检测患者治疗前、后和健康对照组血浆eotaxin、TNF-α和IFN-γ水平.结果 BCG-PSN联合西替利嗪治疗总有效率显著高于单用西替利嗪治疗(88.3%比63.4%,P< 0.05).治疗前两组患者血浆eotaxin、TNF-α和IFN-γ水平差异无统计学意义(均P>0.05).治疗前两组患者血浆eotaxin和TNF-α水平均高于健康对照组(均P<0.05),血浆IFN-γ水平低于健康对照组(P<0.05);两种方案治疗后血浆eotaxin、TNF-α和IFN-γ水平与健康对照组比较,差异均无统计学意义(均P> 0.05).与单用西替利嗪治疗比较,BCG-PSN联合西替利嗪治疗后血浆eotaxin水平下降程度(13.27±4.11比8.12±2.58,t=8.3654,P<0.05)和TNF-α水平下降度(12.38±3.95比10.32±3.41,t=3.1005,P<0.05)更为显著,且IFN-γ水平升高程度(17.06±5.24比12.54±4.07,t=5.3573,P<0.05)更为显著.结论 BCG-PSN联合西替利嗪治疗的临床效果优于单用西替利嗪治疗.
目的 探討卡介菌多糖覈痠(BCG-PSN)聯閤西替利嗪治療慢性蕁痳疹患者,血漿嗜痠性粒細胞趨化因子(eotaxin)、腫瘤壞死因子(TNF)α和榦擾素(IFN)γ水平的檢測.方法 用BCG-PSN聯閤西替利嗪治療慢性蕁痳疹患者,其中聯閤用藥組60例、單獨用藥組63例,觀察兩種治療方案的臨床療效;分彆于治療前、後採集患者和56例健康對照者外週靜脈血;ELISA法檢測患者治療前、後和健康對照組血漿eotaxin、TNF-α和IFN-γ水平.結果 BCG-PSN聯閤西替利嗪治療總有效率顯著高于單用西替利嗪治療(88.3%比63.4%,P< 0.05).治療前兩組患者血漿eotaxin、TNF-α和IFN-γ水平差異無統計學意義(均P>0.05).治療前兩組患者血漿eotaxin和TNF-α水平均高于健康對照組(均P<0.05),血漿IFN-γ水平低于健康對照組(P<0.05);兩種方案治療後血漿eotaxin、TNF-α和IFN-γ水平與健康對照組比較,差異均無統計學意義(均P> 0.05).與單用西替利嗪治療比較,BCG-PSN聯閤西替利嗪治療後血漿eotaxin水平下降程度(13.27±4.11比8.12±2.58,t=8.3654,P<0.05)和TNF-α水平下降度(12.38±3.95比10.32±3.41,t=3.1005,P<0.05)更為顯著,且IFN-γ水平升高程度(17.06±5.24比12.54±4.07,t=5.3573,P<0.05)更為顯著.結論 BCG-PSN聯閤西替利嗪治療的臨床效果優于單用西替利嗪治療.
목적 탐토잡개균다당핵산(BCG-PSN)연합서체리진치료만성담마진환자,혈장기산성립세포추화인자(eotaxin)、종류배사인자(TNF)α화간우소(IFN)γ수평적검측.방법 용BCG-PSN연합서체리진치료만성담마진환자,기중연합용약조60례、단독용약조63례,관찰량충치료방안적림상료효;분별우치료전、후채집환자화56례건강대조자외주정맥혈;ELISA법검측환자치료전、후화건강대조조혈장eotaxin、TNF-α화IFN-γ수평.결과 BCG-PSN연합서체리진치료총유효솔현저고우단용서체리진치료(88.3%비63.4%,P< 0.05).치료전량조환자혈장eotaxin、TNF-α화IFN-γ수평차이무통계학의의(균P>0.05).치료전량조환자혈장eotaxin화TNF-α수평균고우건강대조조(균P<0.05),혈장IFN-γ수평저우건강대조조(P<0.05);량충방안치료후혈장eotaxin、TNF-α화IFN-γ수평여건강대조조비교,차이균무통계학의의(균P> 0.05).여단용서체리진치료비교,BCG-PSN연합서체리진치료후혈장eotaxin수평하강정도(13.27±4.11비8.12±2.58,t=8.3654,P<0.05)화TNF-α수평하강도(12.38±3.95비10.32±3.41,t=3.1005,P<0.05)경위현저,차IFN-γ수평승고정도(17.06±5.24비12.54±4.07,t=5.3573,P<0.05)경위현저.결론 BCG-PSN연합서체리진치료적림상효과우우단용서체리진치료.
Objective To investigate the changes to eotaxin,tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in plasma from patients with chronic urticaria treated with the combination of polysaccharide nucleic acid fraction of bacillus Calmette-Guerin (BCG-PSN) and cetirizine.Methods Totally,123 patients with chronic urticaria were enrolled into this study,and classified into two groups:the combination therapy group (n =60) treated with intramuscular BCG-PSN 2 ml every other day and oral cetirizine 10 mg once daily,and the monotherapy group (n =63) treated with oral cetirizine 10 mg once daily alone.The treatment lasted 54 days.Clinical efficacy was evaluated.Venous blood samples were collected from the patients before and after the treatment,as well as from 56 healthy controls.Enzyme-linked immunosorbent assay was performed to quantify the plasma levels of eotaxin,TNF-α and IFN-γ.Results At the end of the treatment,the total response rate was significantly higher in the combination therapy group than in the monotherapy group (88.3% vs.63.4%,P < 0.05).Before the treatment,no significant differences were observed in the plasma levels of eotaxin,TNF-α or IFN-γ between the two treatment groups,whereas the patients showed higher plasma levels of eotaxin and TNF-α but lower plasma level of IFN-γ compared with the healthy controls (all P < 0.5).Both the combination therapy and monotherapy resulted in a statistical decrease in plasma eotaxin and TNF-α but an increase in plasma IFN-γ (all P > 0.05),and the absolute values of changes in the three parameters were significantly higher in the combination therapy group than in the monotherapy group (eotaxin:(13.27 ± 4.11) μg/L vs.(8.12 ± 2.58) μg/L,t =8.3654,P < 0.05; TNF-α:(12.38 ± 3.95) ng/L vs.(10.32 ± 3.41) ng/L,t =3.1005,P < 0.05; IFN-γ:(17.06 ± 5.24) μg/L vs.(12.54 ± 4.07) μg/L,t =5.3573,P < 0.05).Further more,the differences between the patients and healthy controls in the three parameters disappeared at the end of the treatment (all P > 0.05).Conclusion BCG-PSN combined with cetirizine seems superior to cetirizine alone for the treatment of chronic urticaria.